Cargando…

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE

We report a case of a 42 year-old female, who came to a leishmaniasis reference center in Rio de Janeiro, Brazil, presenting a cutaneous leishmaniasis lesion in the right forearm. Treatment with low-dose intramuscular meglumine antimoniate (MA) (5 mg Sb(5+)/kg/day) was initiated, with improvement af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vasconcellos, Erica de Camargo Ferreira e, Pimentel, Maria Inês Fernandes, Valete-Rosalino, Cláudia Maria, Madeira, Maria de Fátima, Schubach, Armando de Oliveira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Instituto de Medicina Tropical 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131825/ https://www.ncbi.nlm.nih.gov/pubmed/25076440 http://dx.doi.org/10.1590/S0036-46652014000400016

Ejemplares similares

Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study
por: Gagini, Thalita, et al.
Publicado: (2017)

An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil
por: Oliveira-Ribeiro, Carla, et al.
Publicado: (2021)

PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
por: LYRA, Marcelo Rosandiski, et al.
Publicado: (2016)

FACTORS ASSOCIATED TO ADHERENCE TO DIFFERENT TREATMENT SCHEMES WITH MEGLUMINE ANTIMONIATE IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
por: Ribeiro, Madelon Novato, et al.
Publicado: (2014)

Is There Any Difference in the In Situ Immune Response in Active Localized Cutaneous Leishmaniasis That Respond Well or Poorly to Meglumine Antimoniate Treatment or Spontaneously Heal?
por: Leite-Silva, Jéssica, et al.
Publicado: (2023)

Alterations in Evoked Otoacoustic Emissions by the Use of Meglumine Antimoniate in American Tegumentary Leishmaniasis Patients
por: de Oliveira Bezerra, Débora Cristina, et al.
Publicado: (2017)

Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia
por: Rojas Cabrera, Ernesto, et al.
Publicado: (2022)

In Vitro Sensitivity of Paired Leishmania (Viannia) braziliensis Samples Isolated before Meglumine Antimoniate Treatment and after Treatment Failure or Reactivation of Cutaneous Leishmaniasis
por: Baptista, Cibele, et al.
Publicado: (2015)

Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013)
por: Brahim, Lucia Regina, et al.
Publicado: (2017)

FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE
por: Valete-Rosalino, Cláudia Maria, et al.
Publicado: (2014)

The effect of Nd:YAG laser therapy on cutaneous leishmaniasis compared to intralesional meglumine antimoniate
por: Omidian, Mohammad, et al.
Publicado: (2019)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
por: Vargas, Deninson Alejandro, et al.
Publicado: (2019)

Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre
por: da Silva, Rosiana Estéfane, et al.
Publicado: (2016)

Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis
por: Brito, Nayara C., et al.
Publicado: (2019)

Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil
por: Saheki, Mauricio Naoto, et al.
Publicado: (2017)

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis
por: Layegh, Pouran, et al.
Publicado: (2011)

Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
por: Ramalho, Dario Brock, et al.
Publicado: (2018)

Comparison of Intralesional Meglumine Antimonite along with oral Itraconazole to Intralesional Meglumine Antimonite in the treatment of Cutaneous Leishmaniasis
por: Bashir, Uzma, et al.
Publicado: (2019)

Clinical and laboratory profiles of patients with early spontaneous healing in cutaneous localized leishmaniasis: a historical cohort study
por: Oliveira-Ribeiro, Carla, et al.
Publicado: (2017)

Apoptosis and frequency of total and effector CD8(+) T lymphocytes from cutaneous leishmaniasis patients during antimonial therapy
por: Ferraz, Raquel, et al.
Publicado: (2015)

Hoigne Syndrome Caused by Intralesional Meglumine Antimoniate
por: Guarneri, Claudio, et al.
Publicado: (2017)

MONTENEGRO SKIN TEST AND AGE OF SKIN LESION AS PREDICTORS OF TREATMENT FAILURE IN CUTANEOUS LEISHMANIASIS
por: Antonio, Liliane de Fátima, et al.
Publicado: (2014)

Correction: Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
por: Lago, Jamile, et al.
Publicado: (2023)

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
por: Lago, Jamile, et al.
Publicado: (2023)

Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia)
por: Gómez, María Adelaida, et al.
Publicado: (2020)

Two Women Presenting Worsening Cutaneous Ulcers during Pregnancy: Diagnosis, Immune Response, and Follow-up
por: Conceição-Silva, Fátima, et al.
Publicado: (2013)

Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
por: Yazdanpanah, Mohamad Javad, et al.
Publicado: (2011)

Is There Any Difference between the In Situ and Systemic IL-10 and IFN-γ Production when Clinical Forms of Cutaneous Sporotrichosis Are Compared?
por: Morgado, Fernanda N., et al.
Publicado: (2016)

Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate
por: Perez-Franco, Jairo E., et al.
Publicado: (2016)

Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment
por: da Silva, Rosiana Estéfane, et al.
Publicado: (2018)

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
por: Berger, Brandon A., et al.
Publicado: (2017)

Clinical and epidemiological aspects of American cutaneous leishmaniasis with genital involvement()()
por: Lyra, Marcelo Rosandiski, et al.
Publicado: (2020)

Comparison between Colorimetric In Situ Hybridization, Histopathology, and Immunohistochemistry for the Diagnosis of New World Cutaneous Leishmaniasis in Human Skin Samples
por: Ferreira, Luiz Cláudio, et al.
Publicado: (2022)

New World Cutaneous Leishmaniasis Treated with Intralesional Injection of Pentavalent Antimony
por: Shin, Ji Yeon, et al.
Publicado: (2013)

Sporotrichoid leishmaniasis: a cross-sectional clinical, epidemiological and laboratory study in Rio de Janeiro State, Brazil
por: de Carvalho, Livia Martins Veloso, et al.
Publicado: (2017)

Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study
por: Castro, Maria del Mar, et al.
Publicado: (2017)

Dressings Combined with Injection of Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial
por: Khatami, Alireza, et al.
Publicado: (2013)

Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran
por: Aflatoonian, Mohammad Reza, et al.
Publicado: (2019)

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis
por: Berenguer, Diana, et al.
Publicado: (2019)

Therapeutic Potential of Green Synthesized Copper Nanoparticles Alone or Combined with Meglumine Antimoniate (Glucantime(®)) in Cutaneous Leishmaniasis
por: Albalawi, Aishah E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2ohicav0mc9epbh2l87i1f0rlm